Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Viridian Therapeutics, Inc.\DE (VRDN) Return on Capital Employed: 2014-2025

Historic Return on Capital Employed for Viridian Therapeutics, Inc.\DE (VRDN) over the last 11 years, with Sep 2025 value amounting to -0.62%.

  • Viridian Therapeutics, Inc.\DE's Return on Capital Employed fell 18.00% to -0.62% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.62%, marking a year-over-year decrease of 18.00%. This contributed to the annual value of -0.53% for FY2024, which is 6.00% up from last year.
  • Latest data reveals that Viridian Therapeutics, Inc.\DE reported Return on Capital Employed of -0.62% as of Q3 2025, which was up 5.02% from -0.65% recorded in Q2 2025.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Return on Capital Employed ranged from a high of -0.33% in Q4 2022 and a low of -1.28% during Q2 2021.
  • Moreover, its 3-year median value for Return on Capital Employed was -0.50% (2025), whereas its average is -0.55%.
  • Its Return on Capital Employed has fluctuated over the past 5 years, first spiked by 115bps in 2021, then slumped by 33bps in 2023.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Return on Capital Employed (Quarterly) stood at -0.40% in 2021, then grew by 7bps to -0.33% in 2022, then plummeted by 33bps to -0.66% in 2023, then grew by 24bps to -0.42% in 2024, then declined by 18bps to -0.62% in 2025.
  • Its last three reported values are -0.62% in Q3 2025, -0.65% for Q2 2025, and -0.50% during Q1 2025.